Vorinostat (suberoylanilide hydroxamic acid, SAHA), structurally similar to TSA, was the first FDA-approved HDAC inhibitor for the treatment of refractory cutaneous T-cell lymphoma (CTCL) [129]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.